Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

• DOI: 10.1182/blood.2024023930
• Publication Date: 2024-03-29T16:10:51Z
• Authors: Yaqi Zhao; Nicholas J. Short; Hagop M. Kantarjian; Ti-Cheng Chang; Pankaj S. Ghate; Chunxu Qu; Walid Macaron; Nitin Jain; Beenu Thakral; Aaron H. Phillips; Joseph Khoury; Guillermo Garcia-...; Wenchao Zhang; Yiping Fan; Hui Yang; Rebecca S. Garris; Lewis F. Nasr; Richard W. Kriwacki; Kathryn G. Roberts; Marina Konopleva; Elias J. Jabbour; Charles G. Mullighan
• Keywords: Male; Adult; 0303 health sciences; Adolescent; Sialic Acid Binding Ig-like Lectin 2; Middle Aged; 03 medical and health sciences; Antineoplastic Agents, Immunological; Drug Resistance, Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Mutation; Humans; Inotuzumab Ozogamicin; Female; Retrospective Studies

Abstract Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO–treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.